Predictive Oncology Chief Business Officer Pamela Bush and Dom Pollard, the business development manager at Cancer Research Horizons, join Natalie Stoberman from the Proactive studios to discuss their partnership for new cancer drug development.
The collaboration will utilize Predictive Oncology’s PEDAL technology to evaluate Cancer Research Horizons’ pre-clinical drug inhibitors of Glutaminase in order to determine which cancer types and patient populations are most likely to respond to treatment with these compounds. PEDAL is an artificial intelligence and machine learning platform which makes high-confidence drug response predictions enabling a more informed selection of drug-tumor type combinations for clinical development.